Skip to main content

Table 3 Trials testing kava

From: Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review

Reference Study Design Sample Population Intervention Control Length of Treatment Outcomes Direction of Evidence Reported Adverse Events
Volz (1997) [42] Randomized; Double-blind; Parallel Group 101 outpatients with anxiety of non-psychotic origin1 Kava-kava extract WS 1490 (90- 110 mg dry extract = 70 mg kl per capsule) Placebo 24 weeks Significant reduction in anxiety (HAMA, CGI, SCL-90-R, AMS) in favour of kava-kava treatment. + Excellent tolerability, similar to placebo; no clinically relevant changes in laboratory results.
Stomach upset.
Scherer (1998)* [48] Open-label; Uncontrolled Observational study 52 outpatients with nonpsychotic anxiety Kava preparation (no dose reported in abstract) N/A Not reported in abstract 42 patients (80.8%) rated kava treatment as "very good" or "good". + Rare
Malsch (2001) [45] Randomized; Double-blind; Parallel group 40 adult outpatients with non-psychotic nervous anxiety, tension and restlessness, impairing work performance, normal social activities and relationships2 Pre-treatment with benodiazepines (tapered off over two weeks) followed by capsules of 50 mg/day of dry extract standardized to 35 mg kava lactone for three weeks Pre-treatment with benodiazepines (tapered off over two weeks) followed by placebo for three weeks 5 weeks Significant reduction in anxiety (HAMA, Bf-S, EAAS, CGI) in kava-treated group. + No serious adverse events
Watkins (2001) [44] Randomized; Double-blind; Parallel Group 13 patients with GAD Kava 280 mg/day
(standardized to 30% kavalactones)
Placebo 4 weeks Significant improvement in baroreflex control of heart rate in kava-treated group;
respiratory sinus arrhythmia did not respond to kava treatment.
+ Not reported
Connor (2002) [52] Randomized; Double-blind; Parallel Group 38 adults with DSM-IV GAD3 Kava (standardized to 70 mg kavalactones [kl]).
Treatment initiated at 149 mg kl/day and increased to 280 mg kl/day for the next 3 weeks.
Placebo 4 weeks No significant difference to placebo4 - Well tolerated.
No evidence of withdrawal or sexual side effects.
Boerner (2003) [43] Randomized; Double-blind; Parallel Group 129 outpatients diagnosed with GAD (GAD; ICD-10: F41.1) 400 mg/day Kava extract LI 150 (standardized to 30% kavapyrones, extraction solvent 96% ethanol in water, drug-extract ratio 13-20:1) (1) 10 mg/day Buspirone or (2) 100 mg/day Opipramol 8 weeks Kava was shown to be as effective as reference treatments; 75% of patients responded (50% reduction of HAMA score). + 1 treatment-related adverse event.
No systematic difference between treatments.
No liver toxicity reported5.
Cagnacci (2003) [46] Randomized;
Open;
Parallel Groups (3)
80 peri-menopausal women Calcium (1 g/day) plus:
(1) Kava-Kava,100 mg/day (55% of kavaina; Natural Bradel, Milano, Italy)
(2) Kava-Kava, 200 mg/day
Calcium (1 g/day) 3 months Significant reduction in STAI scores in favour of combination treatment. + Mild/moderate:
Nausea
Gastric pain.
No liver toxicity.
Gastpar (2003) [50] Randomized; Double-blind;
Parallel Group
141 adult outpatients diagnosed with neurotic anxiety6 150 mg/day kava special extract WS 1490 (standardized to 35 mg kl) Placebo 4 weeks Pronounced decrease in ASI score for the kava group; however not statistically significant overall; however an exploratory analysis of variance across the differences between treatment end and baseline, with center as a second factor, showed superiority of kava over placebo. - Increased tiredness.
No liver toxicity
Jacobs (2005) [53] Randomized; Double-blind; Parallel Group (3) 391 healthy volunteers with anxiety7 and insomnia (1) 100 mg kl/day kava (30% total kavalactones in extract) with valerian placebo
(2) 6.4 mg/day valerian (1% valerenic acid in extract) with kava placebo
Double placebo 28 days Greater reductions in placebo group, but not statistically significant (STAI-State substest). - Similar frequency between treatments and placebo.
No reports of liver toxicity
Sarris (2009) [47] Randomized;
Double-blind; Crossover
41 adult participants with 1 month or more of elevated generalized anxiety Kava tablets (250 mg/day kavalactones) Placebo 3 weeks Highly significant reduction in anxiety (HAMA, BAI, MADRS) in kava-treated group. + No serious adverse events.
Mild dizziness, nausea.
No liver toxicity.
Sarris (2009) [51] Randomized; Double-blind; Crossover 28 adults with MDD and co-occurring anxiety Hypericum perforatum8
(1 × 1.8 g tablet, three times/day); Kava rhizome aqueous extract9
(1 × 2.66 g tablet, 3 times/day)
Placebo 4 weeks Combination treatment had no significant effects on anxiety (BDI-II). - No serious adverse events.
Mild gastrointestinal upset.
No liver toxicity
  1. HAMA: Hamilton Anxiety Scale; CGI: Clinical Global Impressions; SCL-90-R-ANX: Self-Report Symptom Inventory-90 Items revised, subscore somatic anxiety; AMS: Adjective Mood Scale; kl: kavalactones (kl); Bf-s: Befindlichkeitsskala [subjective well-being score]; EAAS: Erlanger Anxiety, Tension and Aggression Scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; GAD: generalized anxiety disorder; BAI: Beck Anxiety Inventory; BDI-II: Beck Depression Inventory-II; NADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; SARA: Self-Assessment of Resilience and Anxiety; HADS: Hospital Anxiety and Depression Scale.
  2. * No full text available.
  3. 1. DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder and adjustment disorder with anxiety.
  4. 2. Diagnosis of agoraphobia (300.22), simple (300.29) or social phobia (300.23), generalized anxiety disorders (300.02) or adaptation disturbances (309.24) according to DSM-III-R.
  5. 3. According to the Results section, "Thirty-eight subjects were randomized, including 31 female (82%) and 32 Caucasian participants (97%)...Three subjects withdrew their consent following the baseline visit...and did not return for further assessment, leaving 35 subjects in the evaluable sample;" however, the Abstract states: "Thirty-seven adults with DSM-IV GAD were randomly assigned to...treatment."
  6. 4. Post-hoc analyses: kava was superior in low anxiety (SARA) and placebo was superior in high anxiety (HADS; SARA)
  7. 5. Slight increases in transaminase levels to above the upper limit of normal were reported in all three groups.
  8. 6. DSM-III-R diagnoses 300.02, 300.22, 300.23, 300.29, or 309.24.
  9. 7. Scores of at least 0.5 standard deviations above the mean on STAI-State.
  10. 8. Standardized to 990 μg of hypericin, and 1500 μg of flavone glycosides.
  11. 9. Standardized to 50 mg of kavalactones.